Alicia Fong, Research Assistant, Mount Sinai Health System, shared on LinkedIn:
“CML management has evolved from standardized treatment to truly individualized care.
From hydroxyurea and interferon-α to modern tyrosine kinase inhibitors (TKIs), including Imatinib, second-generation TKIs, and asciminib, advances in chronic myeloid leukemia (CML) have transformed treatment outcomes, disease monitoring, and long-term goals.
In this keynote, Dr. Jorge Eduardo Cortes, MD explores frontline TKI selection, molecular response milestones, and how treatment decisions are shaped by survival, tolerability, comorbidities, cost, and the potential for treatment-free remission (TFR).
Beyond treating the disease, effective CML management means continuously reassessing adverse events, quality of life, and what patients want to achieve from their treatment.
Watch the full episode on YouTube, OncoDaily TV.”
Other articles about CML on OncoDaily.
